🔥🐔 BizChicken 🐔🔥

Companies Similar to PMV Pharmaceuticals, Inc.

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Low

ORIC-533, ORIC-944, ORIC-114

ORIC Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers and develops therapies for the treatment of cancers, focusing on overcoming resistance in chemotherapy and immunotherapy. Their product candidates target various cancer resistance mechanisms, including prostate cancer and epidermal growth factor receptor mutations.

Tags: ORIC-114, ORIC-533, ORIC-944, biopharmaceutical, cancer treatment, clinical-stage

Symbol: ORIC

Recent Price: $8.17

Industry: Biotechnology

CEO: Dr. Jacob M. Chacko M.B.A., M.D.

Sector: Healthcare

Employees: 107

Address: 240 East Grand Avenue, South San Francisco, CA 94080

Phone: 650 388 5600

Last updated: 2024-12-31

Pyxis Oncology, Inc.

Pyxis Oncology, Inc. logo
Market Cap: Low
Employees: Lowest

PYX-106, PYX-102, PYX-201, PYX-202, PYX-203

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, focuses on developing therapies to treat various cancers through immune-oncology and antibody drug conjugate product candidates.

Tags: antibody drug conjugate, biopharmaceutical, cancer therapy, immune-oncology, solid tumors

Symbol: PYXS

Recent Price: $1.56

Industry: Biotechnology

CEO: Dr. Lara S. Sullivan M.D., MBA

Sector: Healthcare

Employees: 55

Address: 35 Cambridgepark Drive, Cambridge, MA 02140

Phone: 617 221 9059

Last updated: 2024-12-31

Acrivon Therapeutics, Inc. Common Stock

Acrivon Therapeutics, Inc. Common Stock logo
Market Cap: Low
Employees: Lowest

Acrivon Predictive Precision Proteomics

Acrivon Therapeutics is a clinical stage biopharmaceutical company developing oncology medicines using a proteomics-based platform to identify patient responders. Their lead candidate, ACR-368, is in Phase 2 trials for various cancers.

Tags: ACR-368, CHK1, CHK2, biopharmaceutical, clinical trials, oncology, precision medicine, proteomics

Symbol: ACRV

Recent Price: $5.41

Industry: Biotechnology

CEO: Dr. Peter Blume-Jensen M.D., Ph.D.

Sector: Healthcare

Employees: 58

Address: 480 Arsenal Way, Watertown, MA 02472

Phone: 617-207-8979

Last updated: 2024-12-31

Apollomics, Inc.

Apollomics, Inc. logo
Market Cap: Lowest
Employees: Lowest

APL-101 (Vebreltinib), APL-102, APL-122

Apollomics, Inc. is a biotechnology company that discovers and develops oncology therapies to address unmet medical needs, focusing on treatments for non-small cell lung cancer, liver cancer, breast cancer, esophageal cancer, and brain tumors.

Tags: biotechnology, brain tumors, c-Met inhibitor, cancer therapy, non-small cell lung cancer, oncology, tyrosine kinase inhibitor

Symbol: APLM

Recent Price: $10.13

Industry: Biotechnology

CEO: Dr. Guo-Liang Yu Ph.D.

Sector: Healthcare

Employees: 45

Address: 989 East Hillsdale Blvd, Foster City, CA 94404

Phone: 650 209 4055

Last updated: 2024-12-31

Beam Therapeutics Inc.

Beam Therapeutics Inc. logo
Market Cap: High
Employees: Medium

precision genetic medicines

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.

Tags: Glycogen Storage Disease Type Ia, beta thalassemia, biotechnology, collaboration, genetic medicine, sickle cell disease

Symbol: BEAM

Recent Price: $25.28

Industry: Biotechnology

CEO: Mr. John M. Evans M.B.A.

Sector: Healthcare

Employees: 472

Address: 238 Main Street, Cambridge, MA 02142

Phone: 857 327 8775

Last updated: 2024-12-31

Biomea Fusion, Inc.

Biomea Fusion, Inc. logo
Market Cap: Medium
Employees: Low

BMF-219

Biomea Fusion, Inc. is a biopharmaceutical company specializing in the discovery and development of covalent small molecule drugs for patients with genetically defined cancers and metabolic diseases. Their lead product candidate, BMF-219, targets multiple cancers.

Tags: BMF-219, biopharmaceutical, cancer, covalent drugs, metabolic diseases

Symbol: BMEA

Recent Price: $3.88

Industry: Biotechnology

CEO: Mr. Thomas Andrew Butler

Sector: Healthcare

Employees: 107

Address: 900 Middlefield Road, Redwood City, CA 94063

Phone: 650 980 9099

Last updated: 2024-12-31

Celularity Inc.

Celularity Inc. logo
Market Cap: Lowest
Employees: Low

CYCART-19, CYNK-001, CYNK-101, APPL-001, PDA-002

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and Bio Banking.

Tags: biotechnology, cancer, cell therapies, immune diseases, infectious diseases, placental-derived

Symbol: CELU

Recent Price: $2.05

Industry: Biotechnology

CEO: Dr. Robert Joseph Hariri M.D., Ph.D.

Sector: Healthcare

Employees: 120

Address: 170 Park Avenue, Florham Park, NJ 07932

Phone: 908 768 2170

Leadership

  • Robert J. Hariri, M.D., Ph.D., Chairperson, Founder, and CEO
  • David Beers, CFA, Chief Financial Officer
  • Stephen Brigido, DPM, President, Degenerative Diseases
  • John Haines, Global Manager and Chief Administrative Officer
  • K. Harold Fletcher, Esq., General Counsel & Chief Compliance Officer
  • John Colerangle, DVM, Ph.D., Regulatory Affairs
  • Anna Gosiewska, Ph.D., R&D, Degenerative Diseases
  • Sharmila Koppisetti, M.D., Clinical Development Immunology & Drug Safety
  • Carmine Palummo, Corporate Operations
  • Tim Wilk, Technical Operations
  • Robert J. Hariri, M.D., Ph.D, Chairperson, Founder & CEO
  • Peter Diamandis, M.D., Director
  • Dean Kehler, Director
  • Geoffrey Shiu Fei Ling, M.D., Ph.D., Director
  • Diane Parks, Director

Last updated: 2024-12-31

Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. logo
Market Cap: Medium
Employees: Lowest

Mupadolimab (CPI-006)

Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing immuno-oncology therapies, including Mupadolimab for non-small cell lung cancer, CPI-818 for T-cell lymphomas, and Ciforadenant for renal cell cancer.

Tags: biopharmaceutical, biotech, cancer therapy, clinical trials, immuno-oncology

Symbol: CRVS

Recent Price: $5.25

Industry: Biotechnology

CEO: Dr. Richard A. Miller M.D.

Sector: Healthcare

Employees: 28

Address: 863 Mitten Road, Burlingame, CA 94010

Phone: 650 900 4520

Last updated: 2024-12-31

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

4D-125, 4D-110, 4D-310, 4D-150, 4D-710

4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.

Tags: biotechnology, cardiology, gene therapy, ophthalmology, pulmonology

Symbol: FDMT

Recent Price: $5.30

Industry: Biotechnology

CEO: Dr. David H. Kirn M.D.

Sector: Healthcare

Employees: 201

Address: 5858 Horton Street, EmeryVille, CA 94608

Phone: 510 505 2680

Last updated: 2024-12-31

Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

DNA Medicines

Inovio Pharmaceuticals is a biotechnology company focused on discovering, developing, and commercializing DNA medicines to treat and protect against diseases like HPV, cancer, and infectious diseases. Their platform includes Syn Con designed DNA sequences and CELLECTRA smart devices technology for delivery.

Tags: DNA medicines, HPV, biotechnology, cancer, clinical studies, infectious diseases

Symbol: INO

Recent Price: $1.78

Industry: Biotechnology

CEO: Dr. Jacqueline E. Shea Ph.D.

Sector: Healthcare

Employees: 127

Address: 660 West Germantown Pike, Plymouth Meeting, PA 19462

Phone: 267 440 4200

Leadership

  • Jacqueline Shea, Ph.D., President & Chief Executive Officer
  • Peter Kies, Chief Financial Officer
  • Michael Sumner, MB BS, MBA, Chief Medical Officer
  • Laurent Humeau, Ph.D., Chief Scientific Officer; Chairman, Scientific Advisory Board
  • Steve Egge, MBA, Chief Commercial Officer
  • Rob Crotty, J.D., General Counsel and Chief Compliance Officer
  • EJ Brandreth, MBA, Senior Vice President, Quality Assurance
  • Shawn Bridy, MA, MBA, Senior Vice President, Business Development
  • Cheryl Elder, PharmD, Senior Vice President, Regulatory Affairs
  • Robert J. Juba Jr., Senior Vice President, Biological Manufacturing and Clinical Supply Management
  • Jeffrey Skolnik, M.D., Senior Vice President, Clinical Development
  • Dave Liebowitz, M.D. & Ph.D., Senior Vice President, Early-Stage Clinical Development
  • Simon X. Benito, Chairman of the Board, Inovio Pharmaceuticals
  • Roger D. Dansey, M.D., Chief Medical Officer at Seagen
  • Ann C. Miller, M.D., Former Head of Sanofi Oncology Global Marketing
  • Jay Shepard, Former President & CEO of Aravive
  • David B. Weiner, Ph.D., Executive Vice President, Director, Vaccine Center, The Wistar Institute
  • Wendy L. Yarno, MBA, Former Executive Vice President and Chief Marketing Officer at Merck & Co., Inc.
  • Lota S. Zoth, CPA, Former Chief Financial Officer, MedImmune
  • Rafi Ahmed, Ph.D., Director, Emory Vaccine Center, Emory University School of Medicine
  • Stanley A. Plotkin, M.D., Emeritus Professor, Wistar Institute and University of Pennsylvania; Principal, Vaxconsult

Last updated: 2024-12-31

Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. logo
Market Cap: Low
Employees: Medium

XPOVIO

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on discovering, developing, and commercializing drugs targeting nuclear export for the treatment of cancer and other diseases, with a flagship product named XPOVIO.

Tags: SINE compounds, XPO1, cancer treatment, nuclear export, oncology, pharmaceutical

Symbol: KPTI

Recent Price: $0.70

Industry: Biotechnology

CEO: Mr. Richard A. Paulson M.B.A.

Sector: Healthcare

Employees: 325

Address: 85 Wells Avenue, Newton, MA 02459

Phone: 617 658 0600

Leadership

  • Richard Paulson, President and Chief Executive Officer
  • James Accumanno, Chief Compliance Officer
  • Brian Austad, Senior Vice President, Pharmaceutical Sciences
  • Sohanya Cheng, Chief Commercial Officer and Head of Business Development
  • Lisa DiPaolo, Chief Human Resources Officer
  • Mike Mano, Senior Vice President and General Counsel
  • Michael Mason, Chief Financial Officer
  • Stuart Poulton, Chief Development Officer
  • Reshma Rangwala, Chief Medical Officer & Head of Research
  • Amama Sadiq, Senior Vice President, Global Medical and Scientific Affairs
  • Elhan Webb, Senior Vice President, Investor Relations
  • Garen Bohlin, Director
  • Barry E. Greene, Lead Director
  • Mansoor Raza Mirza, MD, Director
  • Richard Paulson, MBA, President and Chief Executive Officer
  • Christy J. Oliger, Director
  • Deepa R. Pakianathan, PhD, Director
  • Chen Schor, Director
  • Zhen Su, MD, MBA, Director

Last updated: 2024-12-31

Nuvalent, Inc.

Nuvalent, Inc. logo
Market Cap: Highest
Employees: Low

NVL-520 and NVL-655

Nuvalent, Inc. is a clinical stage biopharmaceutical company that develops therapies for patients with cancer, focusing on brain-penetrant inhibitors for ROS1 and ALK.

Tags: ALK inhibitor, ROS1 inhibitor, biopharmaceutical, cancer therapies, clinical trials

Symbol: NUVL

Recent Price: $77.87

Industry: Biotechnology

CEO: Dr. James R. Porter Ph.D.

Sector: Healthcare

Employees: 115

Address: One Broadway, Cambridge, MA 02142

Phone: 857 357 7000

Last updated: 2024-12-31

PDS Biotechnology Corporation

PDS Biotechnology Corporation logo
Market Cap: Low
Employees: Lowest

PDS0101

PDS Biotechnology Corporation is a clinical-stage biopharmaceutical company focused on developing multifunctional cancer immunotherapies. Its lead product candidate, PDS0101, is in Phase II clinical trial for treating various human papillomavirus-associated malignancies.

Tags: biopharmaceutical, cancer immunotherapies, clinical trials, clinical-stage, oncology, vaccines

Symbol: PDSB

Recent Price: $1.69

Industry: Biotechnology

CEO: Dr. Frank K. Bedu-Addo Ph.D.

Sector: Healthcare

Employees: 25

Address: 25B Vreeland Road, Florham Park, NJ 07932

Phone: 800 208 3343

Leadership

  • Frank Bedu-Addo, Ph.D., Chief Executive Officer, Director
  • Stephan Toutain, Chief Operating Officer
  • Lars Boesgaard, Chief Financial Officer
  • Gregory Conn, Ph.D., Chief Scientific Officer
  • Kirk Shepard, M.D., Chief Medical Officer
  • Spencer Brown, Senior Vice-President, General Counsel, Corporate Secretary and Compliance Officer
  • Rory Cullinane, Vice President of Quality
  • Joe Dervan, Ph.D., Vice President of Research and Development
  • David Schaaf, M.D., Vice President of Medical Affairs
  • Sir Richard Sykes, Director
  • Ilian Iliev, Ph.D., Director
  • Gregory Freitag, J.D., CPA, Director
  • Otis W. Brawley, M.D., Director
  • Kamil Ali-Jackson, J.D., Director
  • Stephen Glover, Chairman

Last updated: 2024-12-31

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. logo
Market Cap: Low
Employees: Low

PC14586

PMV Pharmaceuticals, Inc. is a precision oncology company focused on the discovery and development of small molecule and tumor-agnostic therapies targeting p53 mutations in cancer, including lead product candidate PC14586.

Tags: Biotechnology, Cancer Therapies, Precision Oncology, Small Molecules, p53 Mutations

Symbol: PMVP

Recent Price: $1.49

Industry: Biotechnology

CEO: Dr. David H. Mack Ph.D.

Sector: Healthcare

Employees: 63

Address: 8 Clarke Drive, Cranbury, NJ 08512

Phone: 609 642 6670

Last updated: 2024-12-31

Predictive Oncology Inc.

Predictive Oncology Inc. logo
Market Cap: Lowest
Employees: Lowest

Personalized Cancer Therapies

Predictive Oncology Inc. is a knowledge-driven company focusing on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States, operating in four segments: Helomics, z PREDICTA, Soluble, and Skyline.

Tags: Artificial Intelligence, Cancer Therapies, Clinical Testing, Disease Models, Drug Discovery, Genomic Profiling, High-Throughput Chromatography

Symbol: POAI

Recent Price: $0.90

Industry: Medical - Instruments & Supplies

CEO: Mr. Raymond F. Vennare

Sector: Healthcare

Employees: 34

Address: 2915 Commers Drive, Eagan, MN 55121

Phone: 651 389 4800

Last updated: 2024-12-31

Revolution Medicines, Inc.

Revolution Medicines, Inc. logo
Market Cap: Highest
Employees: Medium

RMC-4630

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing therapies targeting frontier targets in RAS-addicted cancers.

Tags: RAS-addicted cancers, cancer therapy, clinical trials, oncology, precision medicine

Symbol: RVMD

Recent Price: $43.17

Industry: Biotechnology

CEO: Dr. Mark A. Goldsmith Ph.D.

Sector: Healthcare

Employees: 378

Address: 700 Saginaw Drive, Redwood City, CA 94063

Phone: 650 481 6801

Last updated: 2024-12-31

Vincerx Pharma, Inc.

Vincerx Pharma, Inc. logo
Market Cap: Lowest
Employees: Lowest

VIP152

Vincerx Pharma, Inc. is a clinical-stage biopharmaceutical company focused on researching and developing therapies to address unmet medical needs for cancer treatment in the United States. Their lead product candidate, VIP152, is a cyclin-dependent kinase-9 inhibitor for advanced cancer.

Tags: biopharmaceutical, cancer treatment, clinical-stage, oncology, therapy development

Symbol: VINC

Recent Price: $0.33

Industry: Biotechnology

CEO: Dr. Ahmed M. Hamdy M.D.

Sector: Healthcare

Employees: 42

Address: 260 Sheridan Avenue, Palo Alto, CA 94306

Phone: 650 800 6676

Last updated: 2024-12-31

Nuvation Bio Inc.

Nuvation Bio Inc. logo
Market Cap: Medium
Employees: Low

NUV-422

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focusing on the development of therapeutic candidates for oncology, such as NUV-422, a small molecule inhibitor targeting cyclin-dependent kinases, among other innovative treatments.

Tags: NUV-422, biopharmaceutical, oncology, therapeutic development

Symbol: NUVB

Recent Price: $2.62

Industry: Biotechnology

CEO: Dr. David T. Hung M.D.

Sector: Healthcare

Employees: 51

Address: 1500 Broadway, New York, NY 10036

Phone: 332 208 6102

Last updated: 2024-12-31

Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. logo
Market Cap: Low
Employees: Lowest

NXP800, NXP900

Nuvectis Pharma, Inc., is a biopharmaceutical company that focuses on developing precision medicines for treating serious unmet medical needs in oncology. It is working on products like NXP800, a heat shock factor 1 pathway inhibitor, and NXP900, a drug candidate targeting Proto-oncogene c-Src and YES1 kinases.

Tags: NXP800, NXP900, biopharmaceutical, oncology, precision medicine

Symbol: NVCT

Recent Price: $5.14

Industry: Biotechnology

CEO: Mr. Ron Bentsur M.B.A.

Sector: Healthcare

Employees: 13

Address: 1 Bridge Plaza, Fort Lee, NJ 07024

Phone: 201 614 3150

Last updated: 2024-12-31

Tango Therapeutics, Inc.

Tango Therapeutics, Inc. logo
Market Cap: Medium
Employees: Low

TNG908

Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.

Tags: BRCA1/2-mutant cancers, Gilead Sciences, STK11-mutant cancers, TNG908, biotechnology, cancer treatment, drug development, methylthioadenosine phosphorylase, protein arginine methyltransferase 5, strategic collaboration, synthetic lethal

Symbol: TNGX

Recent Price: $3.10

Industry: Biotechnology

CEO: Dr. Barbara L. Weber M.D.

Sector: Healthcare

Employees: 140

Address: 100 Binney Street, Cambridge, MA 02142

Phone: 857 320 4900

Last updated: 2024-12-31